Clinical Trials Logo
  1. Home
  2. Other
  3. NCT06340854

A Research Study to See How Switching From a Daily Basal Insulin to a New Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine in Adults With Type 2 Diabetes

Diabetes, Type 2 Clinical Trial

Official title:
A Study to Evaluate the Efficacy and Safety of Once-weekly Insulin Icodec When Switching From Daily Basal Insulins Compared to Once-daily Insulin Glargine U100 in Adults With Type 2 Diabetes

Clinical Trial Summary

This study compares insulin icodec, a new insulin taken once a week, to insulin glargine, an insulin taken once a day. The study medicine will be investigated in participants with type 2 diabetes. Participants will either get insulin icodec or insulin glargine. Which treatment participants get is decided by chance. Insulin icodec is the new medicine being tested, while insulin glargine is already approved and can be prescribed by doctors. Participants will get one injection of insulin icodec once a week, or one injection of insulin glargine once a day, depending on the treatment group participants are assigned into. Participants will use a pen with a small needle to inject the medicine under participants skin into participants thigh, upper arm or stomach.The study will last for about 9 months, but participants will only be taking the study medicine for 6 months.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT06340854
Study type Interventional
Source Novo Nordisk A/S
Contact Novo Nordisk
Phone (+1) 866-867-7178
Email clinicaltrials@novonordisk.com
Status Recruiting
Phase Phase 3
Start date April 19, 2024
Completion date June 20, 2025
View Details
See also
  Status Clinical Trial Phase
Completed NCT01805414 - Breakfast Nutrition and Inpatient Glycemia N/A
Completed NCT01427660 - iDecide.Decido: Diabetes Medication Decision Support Study N/A
Completed NCT02648685 - The Study to Investigate the Contribution of Basal and Postprandial Glucose to Overall Hyperglycemia in T2DM
Completed NCT00141232 - Evaluating Atorvastatin With Omega-3 Fatty Acids in Cardiovascular Risk Reduction in Patients With Type 2 Diabetes Phase 4
Completed NCT03397225 - A Lifestyle Intervention for Type 2 Diabetes Patients in Kuwait and Its Impact on Glycaemic Control N/A
Completed NCT01837680 - Glycemic Control Using Insulin Levemir Versus Insulin NPH for Diabetes in Pregnancy N/A
Completed NCT01336738 - Study Of Safety And Efficacy Of PF-04991532 In Subjects With Type 2 Diabetes Mellitus Phase 2
Completed NCT00308737 - Safety of Inhaled Insulin With Type 1 and Type 2 Diabetes Phase 3
Completed NCT00246987 - A Trial to Evaluate BMS-298585 as Monotherapy in Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control Phase 3
Completed NCT01193179 - A Phase 3 Study of OPC-262 in Patients With Type 2 Diabetes Phase 3
Completed NCT00857558 - A Phase 2 Study of OPC-262 in Patients With Type 2 Diabetes Phase 2
Terminated NCT01350102 - The Relationship of Hemoglobin A1c and Diabetic Wound Healing Phase 4
Completed NCT01624116 - Comparison of Hypoglycaemic Regimens During Ramadan Fasting in Type 2 Diabetes N/A
Completed NCT01634282 - Along-term Study of OPC-262 in Patients With Type 2 Diabetes Phase 3
Withdrawn NCT02222623 - The Inova Type 2 Diabetes Mellitus Study N/A